The dasatinib drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Dasatinib Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.36 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increase in prevalence of chronic myeloid leukemia (CML), growth in targeted cancer therapies, growth in research on tyrosine kinase inhibitors (TKIS), increase in investment in oncology research, and rise in number of clinical trials.
The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing investment in oncology drug pipelines, rising prevalence of drug resistant leukemia cases, growing availability of generic dasatinib drugs, increasing focus on minimizing side effects of chemotherapy, and increasing awareness and early diagnosis of leukemia. Major trends in the forecast period include adoption of personalized medicine, implementation of companion diagnostics, development of new formulations, advancements in combination therapies, and development of biosimilars.
Order your report now for swift delivery @
Scope Of Dasatinib Drugs Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Dasatinib Drugs Market Overview
Market Drivers –
The increasing prevalence of chronic myeloid leukemia (CML) is expected to propel the growth of the dasatinib drug market going forward. Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow and blood and is characterized by the abnormal growth of white blood cells. The rising prevalence of chronic myeloid leukemia (CML) is largely driven by lifestyle demographics, unhealthy eating, and increasing environmental risk factors. Dasatinib drugs are helpful in treating chronic myeloid leukemia (CML) by inhibiting the activity of BCR-ABL (gene fusion), a tyrosine kinase protein produced by the Philadelphia chromosome mutation, which drives the uncontrolled growth of cancerous white blood cells. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, chronic myeloid leukemia (CML) increased to 8,930 compared to 8,860 in 2022 in the United States. Therefore, the increasing prevalence of chronic myeloid leukemia (CML) is driving the dasatinib drug market.
Market Trends –
Major companies operating in the dasatinib drugs market are focusing on developing generic drugs to expand their market share, provide cost-effective treatment options, and increase accessibility for patients. Generic medicines in the dasatinib market offer more affordable treatment options, improving patient access and promoting competition while reducing healthcare costs for patients. For instance, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, launched the first generic version of Sprycel dasatinib in the United States to treat certain types of leukemia in adults and children. This cost-effective alternative improves access to high-quality treatment options. Its introduction marks a significant step in increasing competition and lowering prices in the dasatinib market.
The dasatinib drugs market covered in this report is segmented –
1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare
Get an inside scoop of the dasatinib drugs market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the dasatinib drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP
Table of Contents
1. Executive Summary
2. Dasatinib Drugs Market Report Structure
3. Dasatinib Drugs Market Trends And Strategies
4. Dasatinib Drugs Market – Macro Economic Scenario
5. Dasatinib Drugs Market Size And Growth
…..
27. Dasatinib Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Follow Us On: